Inaktiver Wert

Andere Sprachen Yumanity Therapeutics

Aktien

A2QJX3

US98872L1026

YMTX

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K	11.05.23
Yumanity Therapeutics : Regulation FD Presentation - Form 8-K	17.04.23
Yumanity Therapeutics : VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 - Form 8-K	12.04.23
Yumanity Therapeutics : January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) - Form 8-K	05.01.23
Yumanity Therapeutics : Kineta Completes Reverse Merger with Yumanity Therapeutics - Form 8-K	22.12.22
Kineta's Shares Gain Momentum on Nasdaq Debut Following Yumanity Therapeutics Reverse Merger Completion	19.12.22
Kineta, Yumanity Therapeutics Complete Reverse Merger	19.12.22
YUMANITY THERAPEUTICS, INC. Other Events (form 8-K/A)	16.12.22
Yumanity Therapeutics Inc.(NasdaqCM:KA) dropped from NASDAQ Composite Index	16.12.22
Kineta, Inc. completed the acquisition of Yumanity Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	16.12.22
Yumanity Therapeutics : Acquisition/Asset Disposal - Form 8-K	15.12.22
YUMANITY THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits (form 8-K)	15.12.22
Sector Update: Health Care Stocks Stage Small Recovery Late	14.12.22
Sector Update: Health Care	14.12.22
Top Midday Decliners	14.12.22
Stocks Remain Relatively Flat as Investors Wait for Fed Rate-Hike Move	14.12.22
Investors Remain Sidelined in Premarket Trading Ahead of Fed Decision Wednesday	14.12.22
Top Premarket Decliners	14.12.22
YUMANITY THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	13.12.22
YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	06.12.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Yumanity Therapeutics

Aktien

A2QJX3

US98872L1026

YMTX

Andere Sprachen

Filter